MSF's Suerie Moon spoke in front of a US Senate Committee on promoting new treatments & cures for neglected diseases read more
NEW: The 13th Edition of Untangling the Web of Antiretroviral Price Reductions is now available download it here
VIDEO: MSF's community approach to treating malnutrition in Niger watch it here
WHO's work on the financing of medical research and development is given a fresh start read more
MSF Letter to GFATM on concerns over scale-up of AIDS treatment in light of Board of Directors Meeting read more
New European Parliament Working Group on Innovation & Access launches with support of Access Campaign read more
|
 |
|
 |
Welcome to our campaign update where we let you know what’s been happening with the Make It Happen campaign.
We’ve launched!
Wednesday 7th October: Just over a week since the launch and well over seven thousand emails sent to the drug companies by supporters from as far apart as Japan and Mexico, Myanmar and Burkina Faso. Relief too, in campaign headquarters here in Geneva, that the ‘technicals’ all came together and the launch has gone smoothly so far….
Quote of the Week
|
"With ever higher medicine costs, we need new ideas and fast if we are to continue to be able to treat people living with HIV/AIDS, let alone increase treatment for millions in need. MSF is one hundred per cent behind this patent pool initiative and we will work with others with all our might to give it the support it needs to get off the ground. Please add your voice to ours" |
Further campaign launches coming up….
The campaign is being rolled out country by country and we’re particularly looking forward to the launch in Switzerland later this month when we’re promised that a large inflatable pill will be symbolically dropped into Lake Geneva – we’ll upload some photos when it happens !
And the drug companies’ response?
Early days yet but the German Association of Research-Based Pharmaceutical Companies told reporters this week that drug prices aren’t the issue – rather it’s the lack of medical doctors in developing countries that’s blocking treatment.
Although it is true that holes in infrastructure and human resources are a challenge, determined international efforts are to thank for 4 million patients receiving AIDS treatment today – the vast majority in developing countries.
Drug companies should not divert attention from the issue of high prices but rather take this opportunity to join the patent pool and help build a system where the price of medicines is no longer a barrier for patients in developing countries.
We’ll keep you updated on further responses and let us know if you hear back from the companies too.
Meanwhile, if you have any thoughts about how to get our message out further – events or doing stuff on the web – send your thoughts along to: feedback.msfaccess(a)msf.org
The Myth Busters
Here’s our regular spot where we set about dismantling some of the myths swirling around about patents and access to medicines… this week:
Myth No 1:
We don't need a patent pool because 95% of essential medicines - the medicines included on the World Health Organization's List of Essential Medicines - are off patent
We say:
The 95% figure is true. But this isn’t very relevant to the question of patents on AIDS medicines. WHO’s List of Essential Medicines contains medicines that target all diseases. Most of the medicines on this list are very old and therefore the patents have expired for example penicillins and some anti-TB drugs. Antiretroviral drugs do feature on the list but many of those listed are in fact under patent in one country or another. So this figure of 95% doesn't say much about the need for a patent pool for HIV drugs.
In many African countries, it is true also that many antiretrovirals are not presently patented but that’s not much help either. All too often, those countries don’t have the know how to make their own more affordable, generic versions of the drug. Instead they have to rely on importing these generic drugs from India or other producing countries. Trouble is many of the newer and improved antiretrovirals are nowadays either patented in India or a patent has been applied for. So by putting all the patents into a patent pool, we can ensure that affordable, generic versions of urgently-needed antiretrovirals can be made.
FATAL FLAWS: How Kenya's 2008 Anti-Counterfeit Act could endanger access to medicines 
Presenation: Missing ARVs for HIV/AIDS treatment in 2009 - Unitaid Patent Pool Briefing
HIV/AIDS treatment in developing countries: the battle for long-term survival has just begun
